ABCL AbCellera Biologics Inc.
Financings ·
A later announcement prices 17,435,897 common shares and pre-funded warrants for 3,076,926 shares, for expected gross proceeds of about $200.0 million. The offering is expected to close on August 14, 2026.
AbCellera's common shares last sold at $2.92 per share on February 26, 2025. The prospectus sets no dollar amount for the offerings and names no bank or agent.
AbCellera is a clinical-stage biotechnology company that discovers and develops first-in-class antibody medicines for indications with high unmet medical need. It has moved from using its platform mainly for partners' programs to building its own pipeline. Its lead candidate, ABCL635, is a potential non-hormonal medicine for moderate-to-severe vasomotor symptoms, also known as hot flashes, associated with menopause, and it targets the Neurokinin-3 Receptor. ABCL575, a potential best-in-class antibody targeting OX40 Ligand, is in a Phase 1 trial in Canada for atopic dermatitis and other immunology and inflammation conditions. Two further development candidates, ABCL688 for autoimmune conditions and ABCL386 for oncology, are in IND-enabling activities, and the company anticipates Phase 1/2 trials for both in 2027. The company says its platform targets complex transmembrane proteins, multispecific antibodies and antibody-drug conjugates. It opened a clinical manufacturing facility in Vancouver, which the text describes as 130,000 square feet.
| Product or program | What it is | Stage |
|---|---|---|
| ABCL635 | Antibody for non-hormonal treatment of menopause-associated hot flashes | Phase 1/2 |
| ABCL575 | Antibody for atopic dermatitis and other I&I conditions | Phase 1 |
| ABCL688 | Antibody for autoimmune conditions | IND-enabling studies |
| ABCL386 | Antibody for oncology | IND-enabling activities |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $75.1 million | $28.8 million |
| Research and development | $186.8 million | $167.3 million |
| Net income (loss) | -$146.4 million | -$162.9 million |
| Cash from operations | -$131.3 million | -$108.6 million |
| Cash and equivalents | $128.5 million | $156.3 million |
Our latest story on this, dated Aug 11, 2026: "AbCellera launches $200,000,000 share offering, then prices it at $9.75". The story links the filing or release it is based on. Read the story.
AbCellera Biologics Inc. trades under the ticker ABCL on NASDAQ.
AbCellera Biologics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:8QQ; LS:A2QKXS; LSX:A2QKXS.
The SEC Central Index Key (CIK) for AbCellera Biologics Inc. is 1703057. Its filings are on SEC EDGAR.
306,611,466 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05.
Our directory records AbCellera Biologics Inc. under Canada.
Our directory classifies AbCellera Biologics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for AbCellera Biologics Inc. is CA00288U1066.
aibio.space lists AbCellera Biologics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as A1.
AbCellera is a clinical-stage biotechnology company that discovers and develops first-in-class antibody medicines for indications with high unmet medical need. It has moved from using its platform mainly for partners' programs to building its own pipeline.
ABCL635: Antibody for non-hormonal treatment of menopause-associated hot flashes Stage: Phase 1/2.
ABCL575: Antibody for atopic dermatitis and other I&I conditions Stage: Phase 1.
$75.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
AbCellera Biologics Inc. reported a net loss of $146.4 million for the fiscal year ended Dec 31, 2025, and used $131.3 million of cash in operations, per its annual report to the SEC.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio